Short-term and long-term results of the chemoradiotherapy of the indolent nodal non- Hodgkin's lymphomas of the abdominal and pelvic localization

The aim of this study was to evaluate the short-term and long-term results of chemoradiotherapy of indolent abdominal and pelvic nodal non-Hodgkin lymphomas. The study included 116 patients with primary non-Hodgkin lymphoma who underwent chemoradiotherapy or chemotherapy in the RSCRR from 1980 to 2021. The main group that underwent chemoradiotherapy (ChT+RT) included 63 patients. The control group consisted of 53 people who received only chemotherapy (ChT). In the main and control groups, chemotherapy was applied to identical regimens with or without of Rituximab immunotherapy. The data obtained indicated the advantage of chemoradiotherapy over the chemotherapy in the most patients. After completion of the radiation therapy in the main group, the number of complete remissions increased from 22% to 56% and statistically significantly exceeded the number of those in the control group (28%, P =0.002). The overall survival rate (OS) was significantly higher in the whole ChT+RT group, and in the following subgroups: men, with the Karnovsky index 90-80, III-IV stages, regardless of the size ofthe tumor, in patients of the intermediate risk subgroup, as well as in those with partial remission after RT. The progression-free survival rate (PFS) was significantly higher in the whole ChT+RT group, regardless of gender, in the subgroups with age function show_eabstract() { $('#eabstract1').hide(); $('#eabstract2').show(); $('#eabstract_expand').hide(); }